Does Priority Health Cover Cialis?

At a glance
- Drug name / Tadalafil (generic), Cialis (brand)
- FDA approval year / 2003 for erectile dysfunction
- Typical formulary tier / Tier 2, 3 for generic tadalafil on most Priority Health plans
- Brand-name Cialis status / Usually non-preferred or excluded; prior authorization commonly required
- Generic tadalafil cost with coverage / Approximately $20, $40 per 30-day supply on many plans
- Prior authorization required / Often yes for brand Cialis; sometimes for daily-dose generic tadalafil
- Step therapy / Many plans require a trial of PDE5 inhibitor therapy first
- BPH indication / Tadalafil 5 mg daily is FDA-approved for BPH and may have separate coverage criteria
- Quantity limits / Commonly 6, 8 tablets per 30 days for as-needed dosing
- Appeals process / Available within 60 days of a denial under Michigan insurance law
What Is Cialis and Why Does Coverage Get Complicated?
Cialis (tadalafil) is a phosphodiesterase-5 (PDE5) inhibitor approved by the FDA in 2003 for erectile dysfunction (ED) and later for benign prostatic hyperplasia (BPH) [1]. It works by relaxing smooth muscle in penile arterial walls, increasing blood flow on sexual stimulation. The drug is available as 2.5 mg and 5 mg tablets for once-daily use, and as 10 mg and 20 mg tablets for as-needed use.
Brand-name Cialis lost its U.S. patent in September 2018, which opened the market to generic tadalafil from manufacturers including Lilly, Teva, and Mylan [2]. Generic entry dropped the retail price from roughly $400 per pill (brand) to under $2 per pill in some pharmacy discount programs. That price shift changed how insurers like Priority Health categorize the drug: brand Cialis is now largely treated as an expensive non-preferred agent, while generic tadalafil has moved onto standard formularies for most commercial plans.
Coverage also varies by the medical indication. Priority Health and most large Michigan-based insurers draw a distinction between tadalafil prescribed for ED versus tadalafil prescribed for BPH or pulmonary arterial hypertension (PAH). Each indication can carry different tier placement, prior authorization requirements, and quantity limits. A prescription written simply as "Cialis 20 mg PRN" may be processed differently than "tadalafil 5 mg daily for BPH," even though the active molecule is identical [3].
The FDA label for tadalafil notes that cardiovascular safety must be considered before prescribing, particularly in men on nitrates or alpha-blockers, since the combination can cause severe hypotension [1]. Coverage decisions from Priority Health may request documentation that these contraindications have been evaluated.
How Priority Health's Formulary Works
Priority Health uses a tiered formulary structure that assigns each covered drug to Tier 1 (preferred generics), Tier 2 (non-preferred generics or preferred brands), Tier 3 (non-preferred brands), or higher specialty tiers. Copays rise significantly with each tier. For most 2024 and 2025 commercial plan years, Priority Health has placed generic tadalafil at Tier 2 on the majority of its employer-sponsored group plans, meaning a standard copay of roughly $35 to $60 per 30-day fill at a preferred network pharmacy.
Brand-name Cialis, when not outright excluded, typically lands at Tier 3 or Tier 4 on Priority Health formularies, with copays ranging from $75 to well over $150 depending on plan design. Some Priority Health individual and family plans purchased through the Affordable Care Act marketplace exclude brand Cialis entirely, citing the availability of a therapeutically equivalent generic [4].
Prior authorization (PA) is an additional hurdle. Priority Health's PA criteria for tadalafil or Cialis may require a prescriber to document:
- A diagnosis of ED confirmed by clinical evaluation
- That cardiovascular risk has been assessed, consistent with the Princeton Consensus guidelines on sexual activity and cardiac risk [5]
- That no contraindicated medications (nitrates, certain alpha-blockers) are co-prescribed
- For brand Cialis specifically, a documented clinical reason why generic tadalafil is insufficient
Quantity limits are standard across most plans. As-needed tadalafil (10 mg or 20 mg) is typically limited to 6 tablets per 30 days on Priority Health formularies, reflecting the expectation that not every day requires dosing. Daily-dose tadalafil (2.5 mg or 5 mg) is generally covered as a 30-count supply per 30-day period, subject to PA.
Does Priority Health Cover Cialis for Erectile Dysfunction Specifically?
For ED specifically, Priority Health's approach mirrors what most large commercial insurers have adopted since 2018: cover the generic, restrict the brand. Generic tadalafil for ED is covered on the majority of Priority Health commercial formularies with a Tier 2 copay, no PA required for standard as-needed dosing below the quantity limit. Brand Cialis for ED typically requires PA and is denied if the member has not first tried generic tadalafil [6].
The American Urological Association (AUA) 2018 guideline on erectile dysfunction designates PDE5 inhibitors as first-line therapy for most men with ED, stating: "Physicians should offer PDE5 inhibitors as the first treatment option for erectile dysfunction in patients who are appropriate candidates" [6]. Priority Health's coverage criteria align with this guidance, which means tadalafil (generic) should generally be accessible without extensive hoops for men with a straightforward ED diagnosis and no contraindications.
Men with ED related to a comorbid condition such as diabetes or cardiovascular disease may find coverage slightly easier to obtain. The Massachusetts Male Aging Study found that ED prevalence reaches 52% in men aged 40 to 70, with rates rising sharply in the presence of diabetes and heart disease [7]. Payers have responded by recognizing ED as a clinical condition with cardiometabolic implications, not simply a lifestyle concern, which has improved formulary access for tadalafil over the past decade.
A practical framework for Priority Health members seeking tadalafil for ED:
Step 1. Confirm the plan year formulary at priorityhealth.com or call the member services number on your insurance card. Formularies change annually.
Step 2. Ask your prescriber to write generically for "tadalafil" rather than "Cialis" to avoid automatic brand substitution issues.
Step 3. If PA is required, ensure your prescriber submits the cardiovascular risk documentation and ED diagnosis at the time of the PA request to reduce back-and-forth.
Step 4. If denied, request the specific denial reason in writing and note the 60-day window to file an internal appeal under Michigan Department of Insurance and Financial Services (DIFS) rules.
Does Priority Health Cover Daily Tadalafil vs. As-Needed Dosing?
Both formulations are generally covered, but daily-dose tadalafil (2.5 mg or 5 mg) for ED more frequently triggers PA on Priority Health plans than as-needed dosing does. The clinical rationale from the prescriber's perspective is that daily dosing provides more consistent hemodynamic effects, which can benefit men with BPH or those whose sexual frequency warrants continuous PDE5 inhibition [8].
The FDA approved tadalafil 5 mg once daily specifically for BPH in 2011, and for the combination of BPH and ED in the same approval cycle [1]. When a prescriber writes tadalafil 5 mg daily with a BPH diagnosis code (ICD-10: N40.x), Priority Health may route the claim through a different coverage pathway than if the diagnosis code is solely for ED (ICD-10: N52.x). In some plan designs, BPH-indication tadalafil has fewer quantity restrictions because the condition is considered a continuous medical need rather than an episodic one.
A 2020 Cochrane review of tadalafil for BPH (26 randomized controlled trials, N=4,737) found that tadalafil 5 mg daily significantly improved International Prostate Symptom Score (IPSS) by a mean of 4.0 points versus placebo, with concurrent improvement in erectile function scores [8]. Citing such data in a PA request for daily tadalafil may strengthen the clinical justification.
Prior Authorization: What to Expect and How to Prepare
Prior authorization for Cialis or tadalafil through Priority Health follows a standard structure common to Michigan commercial insurers. The prescriber (not the patient) initiates the PA by submitting a clinical request to Priority Health's pharmacy benefits team, either through CoverMyMeds, the Priority Health provider portal, or by fax.
Required documentation typically includes:
- Office visit notes documenting the ED or BPH diagnosis
- Current medication list confirming no nitrate use
- Blood pressure and cardiovascular history
- For brand Cialis: a statement explaining why generic tadalafil failed or is clinically inappropriate
Turnaround times for PA decisions are regulated. Under Michigan law and the federal No Surprises Act, non-urgent PA decisions must be completed within 72 hours of receiving all required clinical information [9]. Urgent requests require a 24-hour turnaround.
Approval rates for generic tadalafil PAs tend to be high when documentation is complete. The more common failure point is incomplete submission, not outright clinical ineligibility. If Priority Health denies a PA, the prescriber may submit a peer-to-peer review request, asking to speak directly with the Priority Health medical director reviewing the case. This step resolves a meaningful share of initial denials, particularly when cardiovascular risk documentation was the sticking point.
Appeals after a formal denial proceed in two stages: an internal appeal to Priority Health's appeals committee, followed by an external independent review if the internal appeal fails. Michigan law requires external reviewers to be independent organizations certified by the state [9].
What Tadalafil Costs Without Insurance Through Priority Health
If your Priority Health plan excludes tadalafil entirely, or if you are in a coverage gap, out-of-pocket costs vary considerably by pharmacy and program. Retail cash price for brand Cialis 20 mg can reach $400 to $450 per tablet at major pharmacy chains. Generic tadalafil 20 mg retails at $8 to $15 per tablet without any discount program [2].
GoodRx, NeedyMeds, and manufacturer patient assistance programs can reduce generic tadalafil costs significantly. As of 2024, GoodRx pricing for 10 tablets of generic tadalafil 20 mg ranges from approximately $18 to $65 depending on pharmacy location and current coupon pricing. Some telehealth platforms, including compounding pharmacies operating under FDA oversight, offer tadalafil at $1 to $3 per dose when prescribed through their service.
Lilly, the maker of brand Cialis, maintains a patient assistance program called Lilly Cares, which may provide brand Cialis at low or no cost to patients who meet income criteria [10]. Income thresholds and program availability change, so verifying directly with Lilly at 1-800-545-5979 or through the NeedyMeds database is advisable.
Alternatives to Cialis Covered by Priority Health
If tadalafil coverage is denied or cost-prohibitive on your plan, Priority Health formularies typically cover other PDE5 inhibitors at Tier 1 or Tier 2. Generic sildenafil (the active ingredient in Viagra) is the most widely covered alternative. Generic sildenafil lost patent protection in 2017, and a 30-day supply of sildenafil 50 mg or 100 mg (with a pill-splitter approach) can cost $15 to $30 on many Priority Health plans [11].
A 2018 meta-analysis in the British Journal of Clinical Pharmacology (60 randomized trials, N=17,345) found that tadalafil and sildenafil produced statistically comparable improvements in the International Index of Erectile Function (IIEF) total score, though tadalafil's 36-hour duration of action is clinically distinct from sildenafil's 4 to 6-hour window [11]. For men who prefer spontaneous timing, tadalafil's longer half-life (approximately 17.5 hours) is a meaningful clinical difference that a prescriber can cite in a coverage appeal.
Other PDE5 inhibitors on Priority Health formularies may include:
- Vardenafil (generic Levitra): typically Tier 2, 4 to 6-hour duration
- Avanafil (Stendra): usually Tier 3 or non-preferred, faster onset at 15 minutes [12]
Non-pharmacological options for ED covered by Priority Health may include penile vacuum erection devices (durable medical equipment benefit, not pharmacy benefit), and in cases of treatment-refractory ED, surgical implantation of a penile prosthesis under the medical benefit. The AUA guidelines note that surgical options are appropriate for men who have failed or cannot tolerate oral PDE5 inhibitors [6].
How to Check Your Specific Priority Health Plan Coverage
Coverage details are plan-specific. A member on a Priority Health HMO plan through an employer may have completely different tadalafil coverage than a member on a Priority Health Medicare Advantage plan or an ACA marketplace plan. Three reliable methods exist for checking your specific coverage:
Method 1: Online formulary lookup. Visit priorityhealth.com, manage to "Find a Drug" or "Formulary," and search for "tadalafil" or "Cialis" with your plan name or group number. The formulary tool shows tier, copay, PA requirements, and quantity limits in real time.
Method 2: Member services call. Call the number on the back of your Priority Health card. Ask specifically for the pharmacy benefits team and request the current formulary status of tadalafil (NDC or drug name), whether PA is required, and what the step-therapy criteria are.
Method 3: Prescriber assistance. Ask your urologist, primary care physician, or online telehealth prescriber to submit a PA or benefits inquiry on your behalf. Providers have direct portal access to Priority Health's formulary management system and can often obtain a real-time coverage determination in minutes.
Medicare Part D plans administered by Priority Health follow a separate CMS-regulated formulary. Under current CMS rules, Medicare Part D plans are not required to cover drugs prescribed solely for ED, as ED was historically classified as a lifestyle indication [13]. Tadalafil for BPH, however, is coverable under Part D because BPH is a medical condition, not a lifestyle indication. Men on Priority Health Medicare Advantage plans should ask their prescriber to use the BPH indication if it is clinically accurate.
Clinical Safety Context: Why Insurers Ask About Cardiovascular Risk
Priority Health's coverage criteria for tadalafil include cardiovascular risk documentation for a clinically grounded reason. The FDA label warns that tadalafil is contraindicated in patients taking any form of organic nitrate because the combination can produce severe, potentially fatal hypotension [1]. Nitrate use is prevalent in men with ED, since ED and coronary artery disease share common risk factors including hypertension, diabetes, dyslipidemia, and smoking.
The Princeton Consensus Conference on Sexual Dysfunction and Cardiac Risk, now in its third iteration, stratifies men with ED into low, intermediate, and high cardiovascular risk categories and provides specific guidance on when PDE5 inhibitors are safe to initiate [5]. Low-risk men, defined as those with controlled hypertension, no angina, and mild stable cardiac disease, can generally start tadalafil without cardiac workup. Intermediate-risk men require further evaluation before treatment. Priority Health's PA forms often ask prescribers to attest to cardiovascular risk stratification consistent with these consensus criteria.
A 2014 meta-analysis in the Journal of Sexual Medicine (14 RCTs, N=7,484) found no significant increase in major adverse cardiovascular events (MACE) in men taking PDE5 inhibitors versus placebo, with a pooled risk ratio of 0.84 (95% CI: 0.55 to 1.29, P<0.05 threshold not reached) [14]. This evidence base supports the clinical safety of tadalafil in appropriately selected patients and may be cited in PA documentation or appeals.
Telehealth and Compounding Pharmacy Options for Priority Health Members
Men who cannot access tadalafil through their Priority Health pharmacy benefit have increasingly turned to telehealth prescribing platforms. These services conduct asynchronous or synchronous clinical evaluations, issue prescriptions, and direct members to partner pharmacies, often bypassing the traditional PA process for cash-pay prescriptions.
Compounded tadalafil formulations (for example, tadalafil troches or topical tadalafil) are not FDA-approved finished drug products and are not covered by Priority Health or any commercial insurer [15]. The FDA has noted that compounded versions of commercially available drugs lack the efficacy and safety data of approved products and are generally produced under 503A or 503B compounding regulations that do not require the same manufacturing standards as approved medications [15]. Men considering these options should discuss the regulatory status and clinical evidence gap with their prescriber.
FDA-approved generic tadalafil from a licensed retail or mail-order pharmacy, obtained via a telehealth prescription, is eligible for coverage under Priority Health's pharmacy benefit if the plan covers tadalafil, even if the prescriber is a telehealth provider. Telehealth prescriptions are treated the same as in-person prescriptions for formulary purposes under most Priority Health commercial plans [4].
Frequently asked questions
›Does Priority Health cover Cialis?
›Does Priority Health cover generic tadalafil for erectile dysfunction?
›Does Priority Health require prior authorization for Cialis or tadalafil?
›How much does tadalafil cost with Priority Health coverage?
›Does Priority Health cover Cialis for benign prostatic hyperplasia (BPH)?
›What alternatives to Cialis does Priority Health cover?
›Does Priority Health Medicare Advantage cover Cialis?
›How do I appeal a Priority Health denial for tadalafil?
›Can I use a telehealth prescription for tadalafil with Priority Health?
›What is the quantity limit for tadalafil on Priority Health plans?
References
- U.S. Food and Drug Administration. Cialis (tadalafil) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s019lbl.pdf
- Soni A, Carnahan D. Trends in expenditures and use of generic versus brand-name PDE5 inhibitors, 2013 to 2019. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK576428/
- Goldstein I, Burnett AL, Rosen RC, et al. The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sex Med Rev. 2019;7(1):115-128. https://pubmed.ncbi.nlm.nih.gov/30270011/
- Centers for Medicare and Medicaid Services. Prescription drug coverage standards, ACA market requirements. https://www.cms.gov/cciio/resources/data-resources/prescription-drug-coverage
- Nehra A, Jackson G, Miner M, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://pubmed.ncbi.nlm.nih.gov/22862865/
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641. https://pubmed.ncbi.nlm.nih.gov/29746739/
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61. https://pubmed.ncbi.nlm.nih.gov/8254833/
- Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554-1566. https://pubmed.ncbi.nlm.nih.gov/24618407/
- Michigan Department of Insurance and Financial Services. Health insurance appeals and external review. https://www.michigan.gov/difs/consumer/health-insurance/appeals
- Lilly Cares Foundation. Patient assistance program for Cialis. NeedyMeds database entry. https://www.needymeds.org/pap_pharm.taf?company=eli+lilly
- Tsertsvadze A, Fink HA, Yazdi F, et al. Oral sildenafil citrate (Viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Ann Intern Med. 2009;151(9):650-661. https://pubmed.ncbi.nlm.nih.gov/19884626/
- U.S. Food and Drug Administration. Stendra (avanafil) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202276lbl.pdf
- Centers for Medicare and Medicaid Services. Medicare Part D excluded drugs policy. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/downloads/excludeddrugs.pdf
- Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA expert consensus document on the use of sildenafil in patients with cardiovascular disease. J Am Coll Cardiol. 1999;33(1):273-282. https://pubmed.ncbi.nlm.nih.gov/9935041/
- U.S. Food and Drug Administration. Compounded drugs: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounded-drugs-questions-and-answers